NUOBIKAN (02635): Cao Xiaoxue appointed as a member of the nomination committee.
Norbi Can (02635) announced that Mr. Bao Xiaofeng is no longer a member of the company's nomination committee, while independent non-executive director Ms. Cao Xiaoxue has been appointed as a member of the nomination committee, effective from June 10, 2026.
NUOBIKAN (02635) announced that Mr. Bao Xiaofeng has ceased to serve as a member of the Company's nomination committee, while Ms. Cao Xiaoxue, an independent non-executive director, has been appointed as a member of the nomination committee, with effect from June 10, 2026.
Mr. Luo Kuan, a non-executive director, has been appointed as a member of the Company's strategic committee, with effect from June 10, 2026.
Related Articles
HANXBIO-B (03378) spent 1.1521 million Hong Kong dollars to repurchase 43,800 shares on June 10th.
WELLCELL H-NEW (02477) main shareholder, WELLCELL H-NEW Group, plans to sell a total of 576 million shares of the company.
HEARTCARE-B(06609): Ding Kui resigns as non-executive director
HANXBIO-B (03378) spent 1.1521 million Hong Kong dollars to repurchase 43,800 shares on June 10th.
WELLCELL H-NEW (02477) main shareholder, WELLCELL H-NEW Group, plans to sell a total of 576 million shares of the company.
HEARTCARE-B(06609): Ding Kui resigns as non-executive director
RECOMMEND
